XML 19 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
STOCK-BASED COMPENSATION (Tables)
6 Months Ended
Jun. 30, 2012
Stock- Based Compensation

A summary of award activity under the stock option plans as of June 30, 2012 and changes during the six month period is as follows (all options were vested as of June 30, 2012):

 

     Six months ended
June 30, 2012
 
     Shares     Weighted
Average
Exercise
Price
 

Balance, December 31, 2011

     1,903,325      $ 5.07   

Options forfeited/cancelled

     (64,710     8.00   

Options exercised

     —          —     
  

 

 

   

 

 

 

Balance, all exercisable, June 30, 2012

     1,838,615      $ 4.97   
  

 

 

   
Stock Options Outstanding and Exercisable

The following table summarizes information about stock options outstanding and exercisable at June 30, 2012:

 

     Options Outstanding and Exercisable  

Range of Exercise Prices

   Number
Outstanding
and
Exercisable
     Weighted
Average
Remaining
Contractual
Life (Years)
     Weighted
Average
Exercise
Price
 

$ 0.01—$ 3.50

     130,000         4.00       $ 3.49   

$ 3.75—$ 4.82

     1,069,460         1.60         4.45   

$ 5.00—$ 8.72

     539,155         2.23         5.40   

$10.00—$13.00

     100,000         4.00         10.00   
  

 

 

       
     1,838,615         2.08       $ 4.97   
  

 

 

       

Aggregate intrinsic value on June 30, 2012

   $ 1,450         
  

 

 

       
NonVested Restricted Common Stock

A summary of the activity for non-vested restricted common stock awards as of June 30, 2012 and changes during the six months then ended is presented below:

 

     Shares     Weighted
Average
Grant
Fair
Value
 

Balance, December 31, 2011

     2,897,682      $ 4.20   

Granted

     85,000        3.60   

Forfeited

     (16,219     4.38   

Vested

     (78,000     3.54   
  

 

 

   

Balance, June 30, 2012

     2,888,463      $ 4.20   
  

 

 

   
Stock-Based Compensation Expense

The following table summarizes stock-based compensation expense within each of the categories below as it relates to non-vested restricted common stock awards for the six months ended June 30, 2012 and June 25, 2011 (no tax benefits were recognized):

 

     Six Months Ended  
     June 30,
2012
     June 25,
2011
 

Cost of product revenues

   $ 265,503       $ 296,866   

Research and development

     174,101         288,969   

Selling, general and administrative

     1,784,224         884,689   
  

 

 

    

 

 

 

Total

   $ 2,223,828       $ 1,470,524